期刊文献+

Harnessing the HDAC–histone deacetylase enzymes,inhibitors and how these can be utilised in tissue engineering 被引量:4

Harnessing the HDAC–histone deacetylase enzymes,inhibitors and how these can be utilised in tissue engineering
下载PDF
导出
摘要 There are large knowledge gaps regarding how to control stem cells growth and differentiation.The limitations of currently available technologies,such as growth factors and/or gene therapies has led to the search of alternatives.We explore here how a cell’s epigenome influences determination of cell type,and potential applications in tissue engineering.A prevalent epigenetic modification is the acetylation of DNA core histone proteins.Acetylation levels heavily influence gene transcription.Histone deacetylase (HDAC) enzymes can remove these acetyl groups,leading to the formation of a condensed and more transcriptionally silenced chromatin.Histone deacetylase inhibitors (HDACis) can inhibit these enzymes,resulting in the increased acetylation of histones,thereby affecting gene expression.There is strong evidence to suggest that HDACis can be utilised in stem cell therapies and tissue engineering,potentially providing novel tools to control stem cell fate.This review introduces the structure/function of HDAC enzymes and their links to different tissue types (specifically bone,cardiac,neural tissues),including the history,current status and future perspectives of using HDACis for stem cell research and tissue engineering,with particular attention paid to how different HDAC isoforms may be integral to this field. There are large knowledge gaps regarding how to control stem cells growth and differentiation. The limitations of currently available technologies, such as growth factors and/or gene therapies has led to the search of alternatives. We explore here how a cell’s epigenome influences determination of cell type, and potential applications in tissue engineering. A prevalent epigenetic modification is the acetylation of DNA core histone proteins. Acetylation levels heavily influence gene transcription. Histone deacetylase(HDAC) enzymes can remove these acetyl groups, leading to the formation of a condensed and more transcriptionally silenced chromatin. Histone deacetylase inhibitors(HDACis) can inhibit these enzymes, resulting in the increased acetylation of histones, thereby affecting gene expression. There is strong evidence to suggest that HDACis can be utilised in stem cell therapies and tissue engineering, potentially providing novel tools to control stem cell fate. This review introduces the structure/function of HDAC enzymes and their links to different tissue types(specifically bone, cardiac, neural tissues), including the history, current status and future perspectives of using HDACis for stem cell research and tissue engineering, with particular attention paid to how different HDAC isoforms may be integral to this field.
出处 《International Journal of Oral Science》 SCIE CAS CSCD 2019年第2期79-89,共11页 国际口腔科学杂志(英文版)
基金 funded by the EPSRC Centre for Doctoral Training in Tissue Engineering and Regenerative Medicine–Innovation in Medical and Biological Engineering partially sponsored by the EU [FP7/ 2007-2013] for ‘SkelGEN’ consortium (n° 318553) and the British Council
关键词 HDAC CAN BE cells gene has led DNA
  • 相关文献

参考文献4

二级参考文献77

  • 1Bolden JE,Peart MJ,Johnstone RW.Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery,2006.
  • 2C,1991.
  • 3Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 2003; 78: 21-33.
  • 4Fowler JA, Edwards CM, Croucher PI. Tumor-host cell interactions in the bone disease of myeloma. Bone 2011; 48: 121-8.
  • 5Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991; 88: 62-6.
  • 6Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesen- chymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
  • 7Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006; 20: 161- 71.
  • 8Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy- resistant graft-versus-host disease. Transplantation 2006; 81: 1390-7.
  • 9Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: Two case reports. Cell Transplant 2004; 13: 595-600.
  • 10Kim SM, Lim JY, Park Sl, Jeong CH, Oh JH, Jeong M, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res 2008; 68: 9614-23.

共引文献17

同被引文献18

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部